Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | GLA | P06280 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | CDC14B | O60729 | 1/20 | 0.45 |
| ▸ | CDC14A | Q9UNH5 | 1/20 | 0.45 |
| ▸ | CTSD | P07339 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL516118 | 0.83 | ALOX5 (0.52) | ALDH1A1GLAMAPTKDM4EGAA | |
| SCHEMBL30476189 | 0.81 | ALDH1A1 (0.76) | ALDH1A1GLAMAPTKDM4EGAA | |
| SCHEMBL2012858 | 0.81 | ALDH1A1 (0.76) | ALDH1A1GLAMAPTKDM4EGAA | |
| SCHEMBL4586087 | 0.81 | ALDH1A1 (0.53) | ALDH1A1GLAMAPTKDM4EGAA | |
| SCHEMBL29685650 | 0.79 | ALDH1A1 (0.54) | ALDH1A1GLAMAPTKDM4EGAA | |
| SCHEMBL516363 | 0.79 | ALDH1A1 (0.54) | ALDH1A1GLAMAPTKDM4EGAA | |
| SCHEMBL11401526 | 0.77 | ALDH1A1 (0.53) | ALDH1A1GLAMAPTKDM4EGAA | |
| SCHEMBL8820485 | 0.77 | ALDH1A1 (0.49) | ALDH1A1GLAMAPTKDM4ECDC14B | |
| SCHEMBL19760841 | 0.77 | KDM4E (0.54) | ALDH1A1GLAKDM4EMAOALMNA | |
| Silver SCHEMBL11471729 | 0.76 | ALDH1A1 (0.51) | ALDH1A1GLAMAPTKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115568473-A | Use of alkoxypyrazoles as nitrification inhibitors | 巴斯夫欧洲公司 | 2023-01-06 | — | — | CN | disclosed |
| CN-111683529-B | Use of alkoxypyrazoles as nitrification inhibitors | 巴斯夫欧洲公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-111526719-B | Silylethynyl heteroaryl compounds as nitrification inhibitors | 巴斯夫欧洲公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-107580592-B | Thioether compounds as nitrification inhibitors | 巴斯夫欧洲公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-107108385-B | Benzylpropargylethers as nitrification inhibitors | 巴斯夫欧洲公司 | 2021-09-24 | — | — | CN | disclosed |
| CN-107108386-B | Alkynylpyrazoles as nitrification inhibitors | 巴斯夫欧洲公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-112424148-A | Use of substituted 2-thiazolines as nitrification inhibitors | 巴斯夫欧洲公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-112424147-A | Use of substituted thiazolidine compounds as nitrification inhibitors | 巴斯夫欧洲公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-111683528-A | Use of pyrazolylpropargyl ethers as nitrification inhibitors | 巴斯夫欧洲公司 | 2020-09-18 | — | — | CN | disclosed |
| CN-111683529-A | Use of alkoxypyrazoles as nitrification inhibitors | 巴斯夫欧洲公司 | 2020-09-18 | — | — | CN | disclosed |
| CN-111683938-A | Use of N-functionalized alkoxypyrazole compounds as nitrification inhibitors | 巴斯夫欧洲公司 | 2020-09-18 | — | — | CN | disclosed |
| CN-111526719-A | Silylethynyl heteroaryl compounds as nitrification inhibitors | 巴斯夫欧洲公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-105237519-B | Navy blue electroluminescent compounds and its preparation method and application | 北京大学 | 2019-02-22 | — | — | CN | disclosed |
| EP-1320523-B1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER LAMBERT CO (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| EP-1320523-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Warner-Lambert Company LLC (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002024672-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | BCAT1, BCAT2, ABAT | ALDH1A1 642/4885GLA 209/4885MAPT 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.